SRSD384 Investigated for Safety, PK/PD in Overweight/Obese Individuals, Alone and with Tirzepatide

Obesity and Type 2 Diabetes Mellitus (T2DM) are global health crises, often co-occurring and driving significant morbidity and mortality. Current pharmacotherapies, while effective, still leave a substantial unmet need for improved weight loss, glycemic control, and long-term safety profiles. Novel therapeutic agents are continuously sought to enhance metabolic outcomes, either as monotherapy or in combination with established treatments like GLP-1 receptor agonists. This study aims to characterize the initial human profile of SRSD384.

This two-part Phase 1/2 study investigated SRSD384 in overweight or obese participants. Part A evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single subcutaneous (SC) dose of SRSD384 as monotherapy. Part B assessed these same parameters for SRSD384 in combination with tirzepatide in overweight or obese participants also diagnosed with Type 2 Diabetes Mellitus. The study aimed to characterize the initial human profile of SRSD384.

The abstract describes the study design and objectives but does not present specific results or findings. Data regarding the safety, tolerability, pharmacokinetics, or pharmacodynamics of SRSD384 as monotherapy or in combination with tirzepatide are not provided in this record. Therefore, no quantitative outcomes, statistical significances, or effect sizes can be reported from this abstract.